ACADIA Pharmaceuticals Inc. Change in other assets and liabilities

Change in other assets and liabilities of ACAD for past 10 years: annual, quarterly and twelve month trailing (TTM) including Change in other assets and liabilities growth rates and interactive chart.


Highlights and Quick Summary

  • Change in other assets and liabilities for the quarter ending March 30, 2021 was $-2.79 Million (a -137.46% decrease compared to previous quarter)
  • Year-over-year quarterly Change in other assets and liabilities increased by 430.23%
  • Annual Change in other assets and liabilities for 2020 was $-307 Thousand (a -104.08% decrease from previous year)
  • Annual Change in other assets and liabilities for 2019 was $7.53 Million (a -167.62% decrease from previous year)
  • Annual Change in other assets and liabilities for 2018 was $-11.1 Million (a 260.49% increase from previous year)
  • Twelve month Change in other assets and liabilities ending March 30, 2021 was $-1.16 Million (a 276.87% increase compared to previous quarter)
  • Twelve month trailing Change in other assets and liabilities increased by 15.93% year-over-year
Trailing Change in other assets and liabilities for the last four month:
30 Mar '21 30 Dec '20 29 Sep '20 29 Jun '20
$-1.16 Million $-307 Thousand $-4.42 Million $-998 Thousand
Visit stockrow.com/ACAD for comprehensive keystats, realtime prices, income statement, balance sheet, cash flow statement with 10 years of data, and state-of-the-art screener.

Historical Change in other assets and liabilities of ACADIA Pharmaceuticals Inc.

Most recent Change in other assets and liabilitiesof ACAD including historical data for past 10 years.

Interactive Chart of Change in other assets and liabilities of ACADIA Pharmaceuticals Inc.

ACADIA Pharmaceuticals Inc. Change in other assets and liabilities for the past 10 Years (both Annual and Quarterly)

(All values are in $ million)

Year Q1 Q2 Q3 Q4 Fiscal Year
2021 $-2.79
2020 $7.45 $-5.29 $-0.53 $-1.94 $-0.31
2019 $3.33 $-1.87 $8.63 $-5.48 $7.53
2018 $-6.75 $-1.64 $0.39 $-3.76 $-11.14
2017 $6.01 $-6.63 $-4.05 $1.72 $-3.09
2016 $1.24 $3.17 $-4.45 $-2.18 $-2.62
2015 $-1.76 $0.29 $-0.54 $0.22 $-1.8
2014 $1.12 $1.06 $-0.84 $-0.94 $0.4
2013 $-0.15 $-1.28 $0.13 $-1.24 $-2.54
2012 $0.22 $-3.1 $0.03 $0.37 $-2.49
2011 $-0.14 $-0.06 $0.44 $-0.41 $-0.17
2010 $-23.97 $1.37 $-1.67 $-24.7

Business Profile of ACADIA Pharmaceuticals Inc.

Sector: Healthcare
Industry: Biotechnology
ACADIA Pharmaceuticals Inc., a biopharmaceutical company, focuses on the development and commercialization of small molecule drugs that address unmet medical needs in central nervous system disorders. The company offers NUPLAZID (pimavanserin) for the treatment of hallucinations and delusions associated with Parkinson's disease psychosis; Trofinetide, a novel synthetic analog for the treatment of Rett syndrome; ACP-044, a novel first-in-class orally administered non-opioid analgesic for treating acute and chronic pain; and ACP-319, a positive allosteric modulator of the muscarinic receptor for treating cognition and schizophrenia. It is also developing pimavanserin as a treatment for dementia-related psychosis and as an adjunctive treatment for schizophrenia; and pimavanserin as an adjunctive treatment for major depressive disorder. ACADIA Pharmaceuticals Inc. was founded in 1993 and is headquartered in San Diego, California.